Unlocking the Future of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: Growth Rate, Key Trends, and Opportunities for 2025-2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
Analyzing the Growth Rate of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market: What’s the Expected CAGR for the Next Decade?
The market size for EPI (exocrine pancreatic insufficiency) therapeutics and diagnostics has seen robust growth of late. The market is projected to increase from a value of $5.69 billion in 2024 to $6.17 billion in 2025, representing a compound annual growth rate (CAGR) of 8.4%. Factors such as higher incidence of underlying conditions, progress in diagnostic instrument technology, advancements in pharmaceuticals, and increased access to global healthcare services have all contributed to the growth during the historical period.
Anticipated to witness robust growth in the forthcoming years, the market size for therapeutics and diagnostics related to exocrine pancreatic insufficiency (EPI) is projected to rise to $8.32 billion by 2029 at a compound annual growth rate (CAGR) of 7.8%. Factors propelling growth during the forecast period include advancements in telemedicine and remote monitoring, data analytics and artificial intelligence, patient education and support, in addition to shifts in regulatory policies and reimbursement guidelines. The period is also expected to usher in major market trends such as customized treatment strategies, the inception of new therapies, minimally intrusive diagnostics, and cooperative care models.
Which Primary Drivers Are Supporting the Continued Expansion of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics Market?
The uptick in diabetes diagnoses is anticipated to fuel the expansion of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. Diabetes, a chronic metabolic disorder marked by long-term hyperglycemia, results from the body’s inability to sufficiently produce insulin or effectively utilize the insulin it does produce. Treating EPI with pancreatic enzyme replacement therapy (PERT) improves nutrient absorption in diabetic individuals with EPI and enhances their glycemic control. The National Health Service (NHS England), a UK-based publicly funded healthcare organization, revealed that in June 2024, the number of people in England with pre-diabetes identified by the NHS had risen to 3,615,330 by 2023, an 18% rise from 3,065,825 in 2022. Likewise, among those below 40, cases spiked nearly 25%, increasing from 173,166 in 2022 to 216,440 in 2023. Therefore, the swelling number of diabetic individuals is spurring the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market. The escalating incidence of gastrointestinal disorders is predicted to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth. Gastrointestinal diseases, comprising several health conditions that impact the digestive system, are prevalent. Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics are vital for managing these gastrointestinal diseases by substituting deficient enzymes and thereby aiding digestion. As per Crohn’s and Colitis Canada, a non-profit organization, more than 322,600 Canadians were believed to be living with inflammatory bowel diseases (IBD) in June 2023, roughly 0.82% of the populace. Predictions suggest that the prevalence of IBD will continue and approximately 470,000 Canadians or about 1.1% of the population or 1 in 91 people will be living with IBD by 2035. Therefore, the increasing occurrence of gastrointestinal diseases is likely to stimulate the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market’s growth.
Explore Comprehensive Insights Into The Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market With A Free Sample Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
What Are the Leading Organizations Impacting the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market’s Growth?
Major companies operating in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are:
• Pfizer Inc._x000D_
• Merck & Co. Inc._x000D_
• Janssen Pharmaceuticals Inc._x000D_
• AbbVie Inc._x000D_
• Novartis AG_x000D_
What Are the Most Prominent Trends Driving Change in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
Key players in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are opting for strategic partnerships for technological enhancement and to extend their market influence. A strategic partnership refers to a cooperative tie-up between two or more entities pooling their resources, know-how, and endeavors to attain shared goals. An example of this occurred in February 2023 when Codexis, Inc., a protein engineering company from the US, and Nestlé Health Science, a Swiss nutrition science company, unveiled preliminary results from their Phase 1 clinical examination of CDX-7108, a potential therapy for EPI. The findings from this Phase 1 study lay the groundwork for potential future studies, which could significantly enrich the therapeutic choices for EPI patients.
Secure Your Global Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Now for Fast and Efficient Delivery!
Which Segments Play a Crucial Role in the Expansion of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
The exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests, Magnetic Resonance Imaging (MRI), Endoscopic Ultra-Sonography (EUS), Computerized Tomography (CT) Scanning
3) By Drug Type: Generic, Branded
4) By Distribution Channel: Direct Tender, Retail Pharmacy , Third-Party Distributor, Other Distribution Channels
5) By End User: Hospitals, Specialty Clinics, Homecare, Diagnostic Center, Research And Academic Institutes, Other End Users
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Capsule Formulations, Tablet Formulations, Powder Formulations
3) By Lifestyle Modifications Approach: Weight Management, Physical Activity Recommendations, Smoking Cessation Programs
What Regions Are Leading the Charge in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market?
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2024. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does the Definition of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Include?
Exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics refer to treating a condition in which the pancreas does not produce enough digestive enzymes required for the proper breakdown and absorption of nutrients from food in the small intestine. EPI diagnostics and therapeutics play a crucial role in diagnosing and managing exocrine pancreatic insufficiency, helping individuals with EPI achieve better nutrient absorption and overall well-being.
Browse Through More Similar Reports By The Business Research Company:
Gastric Volvulus Treatment Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report
Inflammatory Bowel Disease Treatment Global Market Report 2024
Digestive Health Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/digestive-health-supplements-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
